RT Journal Article
SR Electronic
T1 Age-Specific SARS-CoV-2 Infection Fatality and Case Identification Fraction in Ontario, Canada
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.09.20223396
DO 10.1101/2020.11.09.20223396
A1 Fisman, David N.
A1 Drews, Steven J.
A1 Tuite, Ashleigh R.
A1 O’Brien, Sheila F.
YR 2020
UL http://medrxiv.org/content/early/2020/11/12/2020.11.09.20223396.abstract
AB Background SARS-CoV-2 is a novel pandemic pathogen that displays great variability in virulence across cases. Due to limitations in diagnostic testing only a subset of infections are identified. Underestimation of true infections makes calculation of infection fatality ratios (IFR) challenging.Seroepidemiology allows estimation of true cumulative incidence of infection in populations, for estimation of IFR.Methods Seroprevalence estimates were derived using retention samples stored by Canadian Blood Services in May 2020. These were compared to non-long-term care-linked case and fatality data from the same period. Estimates were combined to generate IFR and case identification fraction estimates.Results Overall IFR was estimated to be 0.80% (0.75 to 0.85%), consistent with estimates from other jurisdictions. IFR increased exponentially with age from 0.01% (0.002 to 0.04%) in those aged 20-29 years, to 12.71% (4.43 to 36.50%) in those aged 70 and over. We estimated that 5.88 infections (3.70 to 9.21) occurred for every case identified, with a higher fraction of cases identified in those aged 70 and older (42.0%) than those aged 20-29 (9.4%). IFR estimates in those aged 60 and older were identical to pooled estimates from other countries.Conclusions To our knowledge these are the first Canadian estimates SARS-CoV-2 IFR and case identification fraction. Notwithstanding biases associated with donor sera they are similar to estimates from other countries, and approximately 80-fold higher than estimates for influenza A (H1N1) during the 2009 epidemic. Ontario’s first COVID-19 pandemic wave is likely to have been accurately characterized due to a high case identification fraction.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunded by the Canadian Institutes for Health Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by the Research Ethics Boards of the University of Toronto and Canadian Blood ServicesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlease contact Dr. Fisman for information on data availability.